← All trials
NCT00334854
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2006
- Primary completion
- May 1, 2010
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 250
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- European Paediatric Soft Tissue Sarcoma Study GroupLead sponsor
- University of PadovaStudy chair
- University of ManchesterStudy chair
- Children's Cancer and Leukaemia GroupCollaborator
- Dutch Childhood Oncology GroupCollaborator
- Italian Association for Pediatric Hematology OncologyCollaborator
- Cooperative Weichteilsarkom Study GroupCollaborator
- Erasmus University RotterdamStudy chair
- University of UlmStudy chair
- University of MilanStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.